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Objective: Tocomparethe compliance, sideeffects and efficacy ofamoxicillin andazithromycin forthe treatment
of Chlamydia trachomatis infection in pregnancy.
Methods: This is a randomized single-blind trial of women diagnosed with C. trachomatis before 33 weeks
gestation.Womenwererandomlyassignedeither500 mgamoxicillin orallythreetimesperdayfor7daysorasingle
dose of 1 g azithromycin orally.Patientswere interviewedbytelephoneapproximately 3–7 daysfollowing therapy
toassesscompliance andsideeffects. Testofcurewas performedata follow-up visit4–6 weeksfollowing comple-
tion of therapy.
Results: Thirty-ninepatientswererandomized with19 receiving amoxicillin and20 receiving azithromycin. There
werenodifferencesin baselinedatabetween the two groups,andtherewereno statistically significantdifferences
insideeffects,compliance orefficacy. In the amoxicillin group84% of women tookall pills,while 100% completed
the single 1 g dose of azithromycin. Side effects were common in both groups (38% overall), with 40% of the
azithromycin groupreportingmoderate toseveregastrointestinalsideeffects compared to17% in the amoxicillin
group(p = 0.11). Of patientswho returnedforfollow-up testof cure,3 of 15 (20%) in the amoxicillin groupwere
positive compared with 1 of 19 (5%) in the azithromycin group (p = 0.3).
Conclusions: Side effects of therapy for C. trachomatis in pregnancy are common. Amoxicillin was slightly better
tolerated than azithromycin. Compliance and cure rates with both regimens was high.
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INTRODUCTION
Chlamydia trachomatis is one of the most common
sexually transmitted diseases (STDs) in the United
States, with a prevalence of 2–24% in pregnant
women1,2. Maternal infection with chlamydia has
been associated with preterm rupture of mem-
branes, preterm delivery, and delayed postpartum
endometritis3. Risks to the neonate include pneu-
monia and conjunctivitis4.
The 1998 Centers for Disease Control (CDC)
treatment guidelines for STDs recommend
erythromycin (500 mg orally four times per day
for 7 days) or amoxicillin (500 mg orally three
times perdayfor7days)asthetreatmentsofchoice
for chlamydia in pregnancy5. It has been well
established that gastrointestinal side-effects are
common with erythromycin use (15–100%).
Severe side effects have resulted in non-
compliance with this therapy at rates of 12–33%.
It has been suggested that amoxicillin is preferable
to erythromycin because it ismore easily tolerated,
has comparable cure rates and is inexpensive6–10.
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Clinical study 197Currently, azithromycin is recommended only
as an alternative agent for treatment of chlamydia
in pregnancy5. This may be due in part to cost
(approximately $20–35 for a course of treatment),
and because there are relatively few studies com-
paring it with other antibiotics in pregnant
women. In fact, the CDC has stated that data are
insufficient to recommend the routine use of
azithromycin in pregnant women5. In practise,
however, azithromycin is often used as a first-line
therapy.Forexample, thestate ofRhodeIslandhas
a program in which all indigent pregnant patients
diagnosed with chlamydial infection are treated
with azithromycin. Azithromycin is reported to
have excellent cure rates, minimal side effects, and
compliance can be virtually ensured given the
one-time dosing regimen10–12.
Based on our Medline review of the literature,
we could find only one randomized trial compar-
ing azithromycin with amoxicillin to treat
chlamydia in pregnancy13. The study showed
similar efficacy for these two agents. More women
were intolerant of azithromycin (10.9%) than
amoxicillin (5.5%), but the difference was not
statistically significant (p = 0.3). The purpose of
this study was to examine the side-effect profile,
compliance and efficacy of azithromycin and
amoxicillin in the treatment of C. trachomatis
infection during pregnancy. We expected to find
no difference in the test of cure between the two
antibiotic treatment groups. However, we hypo-
thesized that there would be a greater number
of side effects and decreased compliance in the
amoxicillin group compared with the azithro-
mycin group.
SUBJECTS AND METHODS
Study Population
Priorto theinitiation ofthestudy,theInstitutional
Review Board approved the protocol and recruit-
ment technique. The site of recruitment for this
trial was the Women and Infants Hospital prenatal
clinic located in the Women’s Primary Care
Center. We invited all pregnantwomen identified
with C. trachomatis infection to participate.
Routine chlamydia screens using ligase chain
reaction (LCR) (Abbott Laboratories, Abbott
Park, IL) are performed on all patients attending
the prenatal clinic. Recruitment criteria included:
positive test for chlamydia prior to 33 weeks
gestation, ability to understand English, and
willingness to give informed consent for participa-
tion. Exclusion criteria included other infections
requiring antibiotic therapy (for example Neisseria
gonorrhoeae or symptomatic vaginitis), known
allergy or sensitivity to either amoxicillin or
azithromycin, or gestational age greater that 33
weeks.
Treatment
After informed consent was obtained, participants
were asked to complete a short questionnaire to
obtain baseline demographic characteristics.
Randomization was performed using a random
number sequence and opaque envelopes for con-
cealment. Patients were randomized to receive
either azithromycin l g orally as a single dose, or
amoxicillin 500 mg orally three times per day for
7 days. Medications were provided free of charge
to patients in both groups. A referral for treatment
was given to all partners of patients testing positive
for chlamydia, and patients were instructed to
abstain fromsexual intercourseuntiltreatment was
completed. If this was not possible, patients were
encouraged to use condoms consistently and
correctly to avoid reinfection.
Approximately 3–7 days post-therapy, a tele-
phone interview with each patient was conducted
to ascertain side effects and compliance with
therapy. The post-therapy questionnaire asked
about gastrointestinal symptoms (e.g. abdominal
pain, nausea, vomiting or diarrhea), rash and other
symptoms. Subjects were asked to rate their side
effects as none, mild, moderate or severe. Partici-
pants who did not finish all their pills were asked
how many pills were remaining. Approximately
4–6 weeks after treatment, a test of cure for
chlamydia using LCR was obtained at a regularly-
scheduled prenatal visit.
Prior to beginning the study, a sample-size
calculation was performed. In order to detect a
20%differenceinefficacybetweenamoxicillin and
azithromycin with a type I error rate (a) of 0.05
and a type II error rate (b) of 0.2 (power of 80%),
50 patientswere needed for each treatment group.
Treatment of chlamydia in pregnancy Kacmar et al.
198 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGYHowever, due to time limitations and difficulties
with recruitment, only 39 patients were enrolled
in this trial.
We performed an intent-to-treat analysis, and
did not omit subjects due to non-compliance or
lack of partner treatment. Continuous data were
analyzed using the unpaired, two-tailed Student
t-test. Categorical variables were analyzed with
chi-squared and Fischer exact test whereappropri-
ate. Non-parametric tests were used to evaluate
the side-effect data that were graded on an ordinal
scale. We used the binomial distribution to place
95% confidence intervals (CI) around proportions
(e.g. cure rates, side effects, etc.).
RESULTS
Between November 1998 and May 2000, 39
patientswere enrolled and randomized.The mean
age of thetotalpopulationwas 21.4 years (standard
deviation (SD) = 5.7), the median gravidity was 2
(range 1–12), and the median parity was 0 (range
0–4). The median gestational age at enrollment
was 12 weeks with a range of 5–31 weeks. In the
study 46% of the patients were Hispanic, 33%
Black, 15% Caucasian and 5% Asian. The two
groups (amoxicillin and azithromycin) did not
differ in terms of race, age, gravidity, parity or
gestational age at enrollment (Table 1).
Of the 39 patients randomized, five failed to
return for follow-up test of cure (four in the
amoxicillin group and one in the azithromycin
group).Ofthe15patientsin theamoxicillin group
who returned for a test of cure, three (20%) had
positive tests of cure, while one of the 19 patients
(5.3%) in the azithromycin group who returned
had a positive test of cure(p = 0.3). Thus,thecure
rate in the amoxicillin group was 80% (95% CI:
51.9–95.7), compared with 94.7% (95% CI:
74.0–99.9) in the azithromycin group. The one
positive test of cure in theazithromycin groupwas
in a patient who did not refer her partner for
treatment, continued to have sexual intercourse
and did not use a condom as recommended. The
three positive tests ofcurein the amoxicillin group
were in women who reported no sexual activity
since treatment.
Intermsofcompliancewiththerapy,all women
in the azithromycin group took the single dose as
directed (100% compliance). Three of 39 patients
(7.7% of total; 15.8% of amoxicillin group) had
pills left at the time of the follow-up phone con-
tact. One patient had a single pill remaining, while
two patients had two pills remaining. The three
patients with positive tests of cure in the
amoxicillin group reported taking all their pills. In
terms of compliance with recommendations
during therapy, only 25 of 39 patients (64%, 95%
CI: 47.2–78.8) stated that their partner was treated
for chlamydia since the patient’s diagnosis was
established.
Whenpatientswere askedwhethertheyexperi-
enced any side effects or ‘bad reactions’ to the
medication, 15 of 39 (38%, 95% CI: 23.4–55.4)
responded affirmatively. Thirty-six per cent
experienced nausea, 38% experienced vomiting,
18% experienced diarrhea and 15% complained of
abdominal pain. Only nausea was statistically asso-
ciatedwith therapyin thefirst trimester (p = 0.04).
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Amoxicillin (n = 19) Azithromycin (n = 20)
Ethnic origin
Caucasian
Black
Hispanic
Asian
Mean age, years (SD)
Median gravidity (range)
Median parity (range)
Mean GA at enrollment, weeks (SD)
3 (15%)
7 (37%)
9 (47%)
0 (0%)
21.7 (6.4)
2 (1–12)
0 (0–3)
13.6 (8.0)
3 (15%)
6 (30%)
9 (45%)
2 (10%)
21.2 (5.1)
2 (1–6)
0 (0–4)
14.8 (7.0)
SD, standard deviation; GA, gestational age
Table 1 Demographic and reproductive characteristics of patients by treatment groupWhen stratified by treatment group, 52.6% (95%
CI: 28.9–75.6) of patients given azithromycin
reported a reaction or side effect, while 29.4%
(95% CI: 10.3–55.6) in the amoxicillin group had
side effects (p = 0.16). The specific side effects
reported are presented in Table 2, stratified by
treatment group. In general, gastrointestinal side
effects were very common, somewhat more so in
the azithromycin group. For example, nausea was
reported in 45% of azithromycin patients and 28%
of amoxicillin patients. Abdominalpain was noted
in 26% of azithromycin patients and 6% of
amoxicillin patients.However,duetosmall sample
size the differences in nausea and abdominal pain
were not statistically significant. Of the
azithromycin patients, 40% experienced moderate
to severe gastrointestinal complaints, while 17% of
amoxicillin patients had moderate to severe
side-effects (p = 0.11). No patients had side effects
severe enough to warrant change of medication.
We foundno relationship between gastrointestinal
complaints post-therapy and reported symptoms
pre-therapy. There were no significant immediate
allergic reactions; however one woman in the
amoxicillin group experienced a rash.
DISCUSSION
Our hypothesis was that there is no difference in
efficacy between azithromycin and amoxicillin.
The three patients with positive tests of cure were
allintheamoxicillin group.Allthreedeniedsexual
intercourse after treatment. Thus, the cure rate in
this group was 80%. We foundone positive test of
cure in the azithromycin group in a woman who
stated she had unprotected intercourse with her
partner who was not treated. Thus, this could
easily be a reinfection rather than a medication
failure. The cure rate in the azithromycin group
was 95%.Ourstudy was underpoweredto detect a
difference in cure rates based on these estimates.
Given thesmall sample sizes ofthe trials performed
to date, one cannot rule out that a difference in
efficacyexists. A properlypoweredstudyisneeded
to provide additional evidence. However, our
results corroborate other studies that showed no
difference in efficacy between erythromycin,
amoxicillin and azithromycin11–14.
As expected, compliance with azithromycin
was quite high. Based on self-report, compliance
with a 7day courseofamoxicillin was also high.In
our study, no patients reported missing more than
two pills. Adair and colleagues12 reported 98%
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Amoxicillin n/total* Azithromycin n/total* p Value
Any reaction or side effect
Nausea
Any
Moderate–severe
Vomiting
Any
Moderate–severe
Diarrhea
Any
Moderate–severe
Abdominal pain
Any
Moderate–severe
GI Side effect
Any
Moderate–severe
Other reactions
Rash
5/17 (29.4%)
5/18 (27.8%)
2/18 (11.1%)
6/18 (33.3%)
3/18 (16.7%)
2/18 (11.1%)
.0/18 (0%)
1/18 (5.6%)
.0/18 (0%)
10/18 (55.6%)
3/18 (16.7%)
1/18 (5.6%)
10/19 (52.6%)
9/20 (45%).
4/20 (20%).
9/20 (45%).
4/20 (20%).
5/19 (26.3%)
3/19 (15.8%)
5/19 (26.3%)
3/19 (15.8%)
13/20 (65%) .
8/20 (40%).
.0 (0%)
0.16
0.27
0.45
0.46
0.79
0.24
0.23
0.18
0.23
0.55
0.11
0.49
*Totals vary due to missing data. GI, gastrointestinal
Table 2 Reported side effects by treatment groupcompliance with azithromycin compared with
54% for erythromycin. Compliance was defined
by Adair and colleagues as strict adherence to
prescription directions.
Wewerevery surprised thatthesideeffectswith
either regimen were so common. Close to 40% of
patients experienced adverse reactions to the
medication. Moderate to severe gastrointestinal
side effects occurred in 40% of azithromycin
patients, while 17% of amoxicillin patients experi-
enced moderate to severe reactions. While this
difference in our study was not statistically signifi-
cant, a two-fold increase in side effects may be
clinically significant.Adairand colleaguesreported
gastrointestinal side effects in 12% of patients
taking azithromycin12, but side effects were deter-
mined by patients’ self-reports rather than system-
atic questioning. Wehbeh and co-workers
reported that 7.4% of patients receiving azithro-
mycin experienced side effects severe enough to
warrant a change in medication15. In contrast, in a
randomized trial of azithromycin versus erythro-
mycin, Bush and Rosa11 noted five of 15 subjects
taking erythromycin were intolerant of the
regimen compared to none of 15 in the azithro-
mycin group. Despite the relatively common
occurrence of side effects in our study, reactions
were not severe enough to require change of
therapeutic regimen.
The strengths of this study include the random-
ized design and a head-to-head comparison of
two commonly used therapeutic regimens for
C. trachomatis infection in pregnancy. The major
limitation of this study is the small sample size. As
a result, we had limited ability to detect clinically
important differences in efficacy and adverse
reactions and a greater chance for type II error.
The small number of subjects results in wide
confidence intervals and a lack of precision in our
estimates. A final limitation is that on generaliza-
tion or external validity. Our results may not
apply to all populations with very different base-
line characteristics.
In a survey of office-based obstetric-
gynecologic practitioners16, McGregor and
colleagues reported that azithromycin was the
preferred treatment for C. trachomatis infection
during pregnancy. However, a Cochrane review
of the literature regarding chlamydia treatment
in pregnancy10 questions how well the safety of
azithromycin use in pregnancy has been estab-
lished. In terms of costs, amoxicillin is the less
expensive alternative. Amoxicillin tablets cost
approximately $0.31 per 500 mg tablet (total dose
for three times a day regimen for 7 days = $6.51)
while azithromycin tablets cost approximately
$6.50 per250 mg tablet(total 1 gdose = $26). In a
decision analysis evaluating antibiotic selection for
C.trachomatisinpregnancy,HuestonandLenhart17
reported that the lowest failure rates could be
achieved with the use of amoxicillin followed
by azithromycin for treatment failures. Costs of
this regimen were approximately 15% lower than
starting withazithromycin.Additionalstudieswith
larger numbersof patientstreated forC. trachomatis
in pregnancy are necessary to determine the
preferred and most cost-effective treatment
regimen.
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